| Identification | Back Directory | [Name]
AS1842856 | [CAS]
836620-48-5 | [Synonyms]
CS-2538
AS1842856
AS 1842856;AS-1842856
5-Amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
5-Amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
3-Quinolinecarboxylic acid, 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- | [Molecular Formula]
C18H22FN3O3 | [MOL File]
836620-48-5.mol | [Molecular Weight]
347.38 |
| Chemical Properties | Back Directory | [Boiling point ]
587.3±50.0 °C(Predicted) | [density ]
1.370±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO:5.0(Max Conc. mg/mL);14.39(Max Conc. mM) | [form ]
A crystalline solid | [pka]
6.47±0.50(Predicted) | [color ]
White to light yellow | [InChI]
InChI=1S/C18H22FN3O3/c1-2-22-9-11(18(24)25)17(23)14-13(22)8-12(15(19)16(14)20)21-10-6-4-3-5-7-10/h8-10,21H,2-7,20H2,1H3,(H,24,25) | [InChIKey]
MOMCHYGXXYBDCD-UHFFFAOYSA-N | [SMILES]
N1(CC)C2=C(C(N)=C(F)C(NC3CCCCC3)=C2)C(=O)C(C(O)=O)=C1 |
| Hazard Information | Back Directory | [Description]
AS-1842856 is a potent inhibitor of forkhead box class O transcription factor 1 (FoxO1; IC50 = 33 nM in HepG2 cells). Inhibition of FoxO1-mediated transactivation with AS-1842856 leads to a dose-dependent decrease in expression of glucose-6 phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) mRNA and inhibits glucogenesis in rat hepatoma Fao cells and a murine model of type 2 diabetes mellitus (T2DM). AS-1842856 also inhibits 3T3-L1 preadipocyte differentiation and reduces lipid droplet growth in adipocytes., | [Uses]
AS 1842856 is a novel FoxO1 antagonist with anti-obesity effects. | [Definition]
ChEBI: AS1842856 is a quinolone that is 4-quinolone substituted at positions 1, 3, 5, 6 and 7 by ethyl, carboxy, amino, fluorine, and cyclohexylamino groups, respectively. It can directly bind to and block the transcription activity of the active forkhead box protein O1 (Foxo1), but not the Ser256-phosphorylated form. It induces cell death and growth arrest in Burkitt lymphoma cell lines at low concentrations. It has a role as a hypoglycemic agent, an anti-obesity agent, an autophagy inhibitor, an antineoplastic agent, an apoptosis inducer and a forkhead box protein O1 inhibitor. It is a quinolinemonocarboxylic acid, a quinolone, an organofluorine compound, a primary amino compound, a secondary amino compound and a tertiary amino compound. | [in vivo]
Oral administration of AS1842856 to diabetic db/db mice leads to a drastic decrease in fasting plasma glucose level via the inhibition of hepatic gluconeogenic genes, whereas administration to normal mice has no effect on the fasting plasma glucose level. Treatment with AS1842856 also suppresses an increase in plasma glucose level caused by pyruvate injection in both normal and db/db mice[1]. | [storage]
Store at -20°C | [References]
[1] TAKEYUKI NAGASHIMA. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice.[J]. ACS Applied Electronic Materials, 2010: 961-970. DOI: 10.1124/mol.110.065714
[2] LONGHUA LIU. FoxO1 antagonist suppresses autophagy and lipid droplet growth in adipocytes.[J]. Cell Cycle, 2016, 15 15: 2033-2041. DOI: 10.1080/15384101.2016.1192732
[3] PENG ZOU. Targeting FoxO1 with AS1842856 suppresses adipogenesis.[J]. Cell Cycle, 2014, 13 23: 3759-3767. DOI: 10.4161/15384101.2014.965977 |
|
| Company Name: |
Spectrum Chemical Manufacturing Corp.
|
| Tel: |
021-021-021-67601398-809-809-809 15221380277 |
| Website: |
www.spectrumchemical.com/oa_html/index.jsp?minisite=10020&respid=22372&language=us |
|